You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
以嶺藥業(002603.SZ):“中醫脈絡學説構建及其指導微血管病變防治”項目獲國家科技進步一等獎
格隆匯 01-10 16:05

格隆匯1月10日丨以嶺藥業(002603.SZ)公佈,2020年1月10日,石家莊以嶺藥業股份有限公司(“公司”)的全資子公司河北以嶺醫藥研究院有限公司(“河北以嶺研究院”)主持的“中醫脈絡學説構建及其指導微血管病變防治”項目榮獲中華人民共和國國務院頒發的2019年度“國家科學技術進步獎”一等獎。河北以嶺研究院為該項目的第一完成單位,公司董事長吳以嶺為該項目的第一完成人。

“中醫脈絡學説構建及其指導微血管病變防治”項目在吳以嶺院士帶領下,自2005年開始歷時十餘年,圍繞微血管病變國際難題,分別從理論(系統構建脈絡學説)、機制(通絡藥物治療微血管病變系列機制)、臨牀(循證醫學研究解決臨牀重大難題)三個方面開展研究並取得重大突破。

此次獲得國家科技進步一等獎,是繼通心絡膠囊治療冠心病研究獲2000年度國家科技進步二等獎、絡病理論及其應用研究獲2006年度國家科技進步二等獎、通心絡蟲類藥超微粉碎技術及應用研究獲2007年度國家技術發明二等獎、參鬆養心膠囊治療心律失常應用研究獲2009年度國家科技進步二等獎以及中藥連花清瘟治療流行性感冒研究獲2011年度國家科技進步二等獎之後,公司獲得的第6項國家科技大獎。這充分體現了公司較強的科研和資源整合轉化升級能力,對於推動公司的科技進步和科技創新、實現公司可持續發展具有重要意義。此次獲獎有助於進一步提升公司品牌影響力和產品市場競爭力,有利於擴大產品市場份額,短期內不會對公司經營業績造成重大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account